<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232293</url>
  </required_header>
  <id_info>
    <org_study_id>RC19_0425</org_study_id>
    <nct_id>NCT04232293</nct_id>
  </id_info>
  <brief_title>Screening of Liver Fibrosis in Patients With Type 2 Diabetes Mellitus</brief_title>
  <acronym>L-FibroT2DM</acronym>
  <official_title>Screening of Liver Fibrosis in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic SteatoHepatitis (NASH), are a
      frequent complication of type 2 diabetes and obesity. This disease has been linked with an
      increased morbidity and mortality, in particular cardiovascular disease and hepatic
      complications (cirrhosis and hepatocellular carcinoma). NAFLD is covered different liver
      damage in ascending order: steatosis, Non-Alcoholic SteatoHepatitis (NASH), fibrosis, and
      finally cirrhosis. Mostly, fibrosis has a determining role in the patient's status health.
      The fibrosis prevalence rate may reach up to 15 % of people with type 2 diabetes. The purpose
      of the study is to screen hepatic fibrosis for patient with type 2 diabetes.

      To be sure of the status of the disease, the gold standard procedure remains liver biopsy.
      However, it's an invasive procedure and it's a challenge to perform this kind of medical
      procedure to every patient with NAFLD. Some alternative procedure exists, called FibroScan
      that gives some indication of liver fibrosis status. Unfortunately, every diabetologist
      hasn't this equipment in his medical office. The investigators propose to evaluate two
      non-invasive biological fibrosis tests, called eLIFT and FibroMeter. The results of these two
      diagnostic tests will be compared to FibroScan and to liver biopsy results.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eLift and FibroMeter sensitivity for the diagnosis of advanced hepatic fibrosis</measure>
    <time_frame>Day 0</time_frame>
    <description>sensitivity calculated as follows: (number of patients with advanced hepatic fibrosis and a positive test) / (number of patients with advanced hepatic fibrosis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of advanced hepatic fibrosis diagnosed according to the FibroScan composite criterion and then liver biopsy</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Controlled Attenuation Parameter (CAP) measurement by FibroScan</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient rate with eLIFT ≥8 versus FibroMeter ≥0.22.</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver hardness (kPa) measured by FibroScan</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication of diabetes</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">806</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>NAFLD</condition>
  <condition>NASH</condition>
  <arm_group>
    <arm_group_label>Blood tests</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two diagnostic tests (eLift and FibroMeter) will be performed to evaluate liver fibrosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood tests</intervention_name>
    <description>eLift and FibroMeter</description>
    <arm_group_label>Blood tests</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 40 years old,

          -  Type 2 diabetes mellitus for more than 6 months,

          -  BMI &gt; 25 kg/m2,

          -  Waist circumference &gt; 94 cm (male) or 80 cm (female).

        Exclusion Criteria:

          -  Medical follow up for liver disease,

          -  Decompensated cirrhosis,

          -  Health status that does not allow the participation of the patient,

          -  Hospitalisation for acute complication: sepsis, infection, foot's ulcer, acute
             coronary syndrome,…

          -  HbA1c &gt; 11,0 %,

          -  Pregnancy.

          -  Patient under guardianship or curatorship or protection of justice

          -  Involvement refusal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand CARIOU, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes Hospital University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bertrand CARIOU, Pr</last_name>
    <phone>2.53.48.27.07</phone>
    <phone_ext>+33</phone_ext>
    <email>bertrand.cariou@univ-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jérôme BOUSIER, Pr</last_name>
    <email>Jeboursier@chu-angers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jérôme BOURSIER, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Jérôme BOURSIER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bertrand CARIOU, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Bertrand CARIOU, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NASH</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

